Topiramate in Adolescents With Severe Obesity

PHASE2CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

June 30, 2013

Primary Completion Date

December 31, 2015

Study Completion Date

April 30, 2017

Conditions
Obesity, MorbidObesityWeight Loss
Interventions
DRUG

Topiramate

Topiramate will be initiated at a dose of 25 mg (taken orally once daily in the evening), escalated to 50 mg (taken orally once daily in the evening) after 1 week, and escalated to 75 mg (taken orally 25 mg in the morning and 50 mg in the evening) after 2 weeks. Patients who do not tolerate dose escalation will be reduced to the highest tolerated dose for the remainder of the trial.

OTHER

Placebo

Placebo will be taken orally once daily in the evening for the first two weeks, and orally twice daily (AM and PM) for the remainder of the study.

Trial Locations (1)

55455

University of Minnesota, Minneapolis

All Listed Sponsors
lead

University of Minnesota

OTHER

NCT01859013 - Topiramate in Adolescents With Severe Obesity | Biotech Hunter | Biotech Hunter